Alan L Matsumoto MD

Alan K. Matsumoto, M.D., FACR, FACP

Education and Training: B.S. 1981 Stanford University, Chemistry; M.D. 1985 University of Illinois at Chicago; Internship/ 1985-1988 University of Medicine and Residency Dentistry of New Jersey Robert Wood Johnson Medical School Internal Medicine; Chief Resident 1987-1988 Medical Center at Princeton; Fellowship 1988-1993 Johns Hopkins University Rheumatology

Professional Experience: Private Practice, Partner Arthritis and Rheumatism 2002-present

Associates, Wheaton , MD; Management Executive Committee 2005-present; Director, IT and Electronic Health Record 2008-present; Director Clinical Laboratory 2011- present; Assistant Professor of Medicine Johns Hopkins University 1993 – 2002; Full time faculty Division of Rheumatology; Part-Time faculty 2002-present; The Rheumatology Educators Group (TREG) - partner

RESEARCH ACTIVITIES: Publications: Schmid SL, Matsumoto AK, Rothman JE. 1981. A Domain of Clathrin that Forms; Coats, Proc. Natl. Acad. Sci., 79, 91-96; Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT.; 1991. Intersection of the Complement and Immune System: A Signal Transduction; Complex of the B Lymphocyte Containing Complement Receptor Type 2 and CD19.; J. Exp. Med., 173, 55-64.; Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. 1991. Molecular Interactions of Complement Receptors on B Lymphocytes: A CR1/CR2 Complex Distinct form the CR2/CD19 Complex, J. Exp. Med., 173, 1083-1089.; Kalli KR, Hsu P, Bartow TJ, Ahearn JM, Matsumoto AK, Klickstein LB, Fearon DT. 1991. Mapping of the C3b-binding Site of CR1 and Construction of a (CR1)2-F(ab')2; Chimeric Complement Inhibitor, J. Exp. Med., 174, 1451-1460.; Matsumoto AK, Martin DR, Carter RH, Ahearn JM, Klickstein LB, Fearon DT. 1993. Functional Domains Mediating the CD21/DC19/TAPA-1/Leu-13 Complex on B Lymphocytes, J. Exp.l Med., 178, 1407-1417.; Moreland LW, Koopman WJ, Adamson TC, Calabrese LH, Cash JM, Markeson JA, Matsumoto AK, et al. 1998. T Cell Receptor Peptide vaccination in RA: A Placebo Controlled trial Using a Combination of Vβ3, Vβ14, and Vβ17 Peptides. Arthritis Rheum, 41:1919-1929.; Matsumoto AK, Moore R, Alli P, Wigley FM. 1999. Three Cases of Osteonecrosis of the Lunate Bone of the Wrist, Clin Exp Rheum. 17(6):730-732.; Rastegar DA, Claiborne CV , Fleisher AS, Matsumoto AK. 2001. Primary HIV Infection Presenting with Acute Rhabdomyolysis. Clin Infectious Disease, 32(3): 502-504.; Matsumoto AK, Melian A, Mandel DR, et al. 2002: A Randomized, Controlled, Clinical Trial of Etoricoxib in the Treatment of Rheumatoid Arthritis. J Rheumatol 29:1623-30.; Furst DE, Saag K, Fleishmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Deitz F, Sack M, Senter RG, Wiessenhunter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moerland LW, Hurd E, Yocum D, Stamler DA. 2002. Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Who Have Been Treated with methotrexate: A Six Month, Double-Blind, Randomized Dose-Ranging Study. Arthritis Rheum. 46:2020-2028.; Bartlett SJ, Piedmont R, Bilderback A, Matsumoto AK, Bathon JM. 2003. Spirituality, Well-being and Quality of Life in People with Rheumatoid Arthritis. Arthritis Rheum 49(6): 778-783.; Matsumoto AK, Cavanaugh PF. 2004 Etoricoxib. Drugs of Today n40(5):395-414.; Battisti WP, Katz NP, Weaver AL, Matsumoto AK, et al. 2004. Pain management in osteoarthritis: focus on onset of efficacy—comparison of rofecoxib, celecoxib, acetaminophen and nabumetone across four clinical trials. J Pain 5(9)511-520.; Matsumoto AK, Babul N, Ahdieh H.Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial..Pain Med 2005. 6(5) 357-66.; Matsumoto AK. Oral extended-release oxymorphone: a new choice for chronic pain relief. Expert Opin Pharmacother. 2007 Jul;8(10):1515-27. Review.; Baraf HS, Matsumoto AK, Maroli AN, et al. Resolution of gouty tophi after twelve weeks of peloticase treatment. Arthritis Rheum 2008 58 (11): 3632-4.; Baraf HS, Matsumoto AK. Pegloticase: New biologic for treating gout. Int J Clin Rheumatol 2012 7(2) 143-154.; Cohen S, Pablos JL, Pvelka K, Muller GA, Matsumoto A, et al. An open label extension study to demonstrate long term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. Arthritis Res Ther 2019 Mar 29; 21 (1):84.

Book Chapters; Matsumoto AK. 2006 Pharmachologic Interventions: Biologic Therapy In SJ Bartlett, CO Bingham, MJ Maricic et al (eds): Clinical Care in the Rheuamtic Diseases 3rd Edition. Association of Rheumatology Health Professionals, Atlanta, GA; Matsumoto AK. 2004. Arthritis. In RG Miller, BH Ashar, SD Sisson (eds): The Johns Hopkins Internal Medicine Board Review. Mosby, Philadelphia, PA.; Matsumoto AK. 2003. Rheumatoid Arthritis. In LRBarker, JR Burton, PD Zieve, N Fiebach, DE Kern, P Thomas, R Ziegelstein (eds): Principles of Ambulatory Medicine 6th Edition. Lippincott, Williams and Wilkins, Baltimore, MD.; Bathon JM, Matsumoto AK. 2001. Anti-tumor necrosis factor agents . In Tsokos G, Moreland LM, Martel-Pelletier J, Gay S (eds): Modern Therapeutics in Rheumatic Diseases.; Wigley FM, Matsumoto AK. 2000. Scleroderma. In MH Weisman ME Weinblatt (eds): Treatment of Rheumatic Diseases. Saunders, Philadelphia, PA.; Matsumoto AK, Wigley FM. 1998. Rheumatoid Arthritis. In LR Barker, JR Burton, PD Zieve (eds): Principles of Ambulatory Medicine 5th Edition. Williams and Wilkins, Baltimore, MD 988-1010.; Wigley FM, Matsumoto AK. 1995. Scleroderma. In MH Weisman, ME Weinblatt (eds): Treatment of Rheumatic Diseases. Saunders, Philadelphia, PA 172-191.; Wigley FM, Matsumoto AK. 1995. Raynaud's Phenomenon. In MH Weisman, ME Weinblatt (eds): Treatment of Rheumatic Diseases. Saunders, Philadelphia, PA 192-200.

EDUCATIONAL ACTIVITIES: Teaching: (recent selected activities); Johns Hopkins Arthritis Website- “Biologic Agents and Malignancy” Webcast 2010; Lecturer, Johns Hopkins University Medical Student Pathophysiology Course 1993-2010; Johns Hopkins Rheumatology Update 2010- presenter- “What’s New in Gout”; The Rheumatology Educators Group ( TREG) 2010- present;

CLINICAL: Certification: State of Maryland, Physician's License, #D0036867, Expiration - 09/30/2017; Specialty Certification: American Board of Internal Medicine, 1988; American Board of Internal Medicine, Rheumatology,1990; re-certification Rheumatology 2002

ORGANIZATIONAL ACTIVITIES: American College of Physicians, Fellow; American College of Rheumatology, Fellow; Professional Improvement Module Committee 2006; Continuing Assessment Review Evaluation Committee 2006, 2007; Communications and Marketing Committee 2010-2013; Registries Health Information and Technology Committee 2014- 2017; ACR representative to Physician EHR Committee; National meeting abstract selection committee 2012-2014, 2016-2017; Rheumatism Society District of Columbia, President, 2003-2004; Planning committee 2004-present

RECOGNITION: Departmental Honors in Chemistry, 1981; Alpha Omega Alpha, elected as housestaff, 1988; Howard Hughes Postdoctoral Fellowship for Physicians, 1991-1993; Teacher of the Year, Johns Hopkins Bayview Medical Center, 1996; Fellow, American College of Rheumatology; Fellow, American College of Physicians